Is NCT03212131 results overdue?

Yes — results are overdue. Primary completion was 2018-03-08; the FDAAA-801 reporting deadline (2019-03-08) passed 2708 days ago and no results are posted on ClinicalTrials.gov.

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

NCT ID	NCT03212131 ↗
Sponsor	Novo Nordisk A/S (INDUSTRY)
Public issuer	NOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
Phase	PHASE1
Status	COMPLETED
Primary completion	2018-03-08 (ACTUAL)
Reporting deadline	2019-03-08 (completion + 365d)
Days overdue	2708
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `a1525bb88fb1d129…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03212131. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.